Andrew J. Gretlhein, Ph.D., is a seasoned biotechnology executive with over 25 years of experience in pharmaceutical operations, clinical development, and strategic leadership. Holding a Ph.D. in Molecular Biology from Stanford University, he began his career at Genentech, where he advanced from research scientist to director of process development, contributing to the successful commercialization of several monoclonal antibody therapies. His early achievements include optimizing manufacturing processes that reduced production costs by 40% for Herceptin, earning him recognition as a key innovator in bioprocessing. Throughout his career, Dr. Gretlhein held progressively senior roles at biotech firms such as Amgen and Gilead Sciences, where he spearheaded global supply chain initiatives and regulatory submissions, leading to FDA approvals for three novel therapeutics. Notable accomplishments include scaling operations for a Phase III oncology program at Gilead, which accelerated market entry by 18 months, and implementing quality systems that achieved zero major FDA observations during multiple inspections. His expertise in navigating complex regulatory landscapes and fostering cross-functional teams has been instrumental in driving operational excellence across the industry. As Former Executive Vice President and Chief Operating Officer at Geron Corporation, Dr. Gretlhein oversaw all operational functions, including manufacturing, clinical operations, and supply chain management, from 2015 to 2022. Under his leadership, Geron advanced its telomerase inhibitor imetelstat through pivotal clinical trials, culminating in a successful Biologics License Application submission. He played a pivotal role in streamlining operations to support the company's transition from R&D-focused to commercial-ready entity, enhancing efficiency and positioning Geron for long-term growth in regenerative medicine.